CChemical inhibitors of 2310016E02Rik can exert their inhibitory action through diverse molecular pathways, each targeting a specific aspect of the protein's function. Staurosporine, a potent kinase inhibitor, can impede the function of 2310016E02Rik by broadly inhibiting the phosphorylation processes essential for its activity. This universal blockade of kinase activity can lead to a wide-ranging suppression of 2310016E02Rik's functional role in cellular signaling. Similarly, Bisindolylmaleimide I can inhibit 2310016E02Rik by specifically targeting Protein Kinase C (PKC), thereby disrupting the PKC-mediated signaling pathways that 2310016E02Rik may rely on. LY294002, by inhibiting PI3K, can obstruct the PI3K/AKT pathway, which is often crucial for the activation and function of proteins like 2310016E02Rik. Rapamycin, by inhibiting mTOR, can disrupt signaling pathways associated with mTOR that are necessary for 2310016E02Rik's activity.
Further, inhibitors like PD98059 and U0126 can impede the function of 2310016E02Rik by selectively blocking MEK1/2, which is integral to the MEK/ERK pathway, a signaling cascade that 2310016E02Rik may be regulated by. SB203580 targets the p38 MAPK signaling pathways, which can inhibit 2310016E02Rik if its function is associated with p38 MAPK activity. SP600125 acts upon JNK, and its inhibitory effect can prevent JNK-mediated signaling that is essential for the activity of 2310016E02Rik. PP2, by selectively inhibiting Src family tyrosine kinases, can disrupt signaling pathways that rely on these kinases for the regulation of 2310016E02Rik. Dasatinib, which inhibits Src family kinases and c-KIT, can block the pathways controlled by these kinases that may be crucial for the function of 2310016E02Rik. Erlotinib, by targeting EGFR tyrosine kinase, can interfere with EGFR signaling pathways that are necessary for 2310016E02Rik's function. Lastly, Sorafenib's inhibition of multiple kinases, including RAF, can impede RAF signaling pathways that are essential for the functional activity of 2310016E02Rik.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine inhibits a broad range of protein kinases, which could lead to the functional inhibition of 2310016E02Rik by preventing phosphorylation processes that are essential for its activity. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I, a specific inhibitor of Protein Kinase C, can inhibit 2310016E02Rik by interfering with PKC-mediated signaling pathways, potentially essential for 2310016E02Rik function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 inhibits PI3K, and by doing so, it can inhibit 2310016E02Rik by blocking the PI3K/AKT pathway, which may be crucial for 2310016E02Rik's activation and function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which can lead to the functional inhibition of 2310016E02Rik by disrupting mTOR signaling pathways that may be necessary for 2310016E02Rik's activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 selectively inhibits MEK1/2, which could lead to the functional inhibition of 2310016E02Rik by blocking the MEK/ERK pathway, possibly involved in the regulation of 2310016E02Rik. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, and its inhibition can lead to the functional inhibition of 2310016E02Rik by interrupting MEK/ERK signaling, likely implicated in 2310016E02Rik's function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 specifically inhibits p38 MAPK, which can inhibit 2310016E02Rik by blocking the p38 MAPK signaling pathways that could be critical for the activity of 2310016E02Rik. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, which can lead to the functional inhibition of 2310016E02Rik by preventing JNK-mediated signaling events that are essential for 2310016E02Rik's activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases, which can inhibit 2310016E02Rik by disrupting Src family kinase-dependent signaling pathways involved in 2310016E02Rik's regulation. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib, by inhibiting Src family kinases and c-KIT, can inhibit 2310016E02Rik by blocking the signaling pathways controlled by these kinases, which are potentially crucial for 2310016E02Rik's function. | ||||||